AstraZeneca’s Imfinzi (durvalumab) Receives NMPA’s Approval for Unresectable Stage III Non-Small Cell Lung Cancer

 AstraZeneca’s Imfinzi (durvalumab) Receives NMPA’s Approval for Unresectable Stage III Non-Small Cell Lung Cancer

AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

Shots:

  • The approval is based on P-III PACIFIC study assessing Imfinzi vs PBO in 713 ‘all-comer’ patients (regardless of PD-L1 status) with unresectable, Stage III, LA NSCLC whose disease had not progressed following concurrent platinum-based CRT
  • The P-III PACIFIC study results: improvement in OS and PFS; 32% reduction in risk of death; mPFS (16.8 vs 5.6mos.)
  • Imfinzi (durvalumab) is a mAb targeting PD-L1, blocking the interaction of PD-L1 with PD-1 and CD80, approved in 54 countries for stage III NSCLC following CRT

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Daily Camera

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post